[Edaily Reporter Kim Hyung-il ] NanoenTek,Inc.(039860)announced on the 17th that it is expanding its wellness and longevity business by launching three women’s health diagnostic products in the U.S. market and continuing its beauty tech collaboration with L’Oréal.
NanoenTek,Inc. CI. (Photo courtesy of NanoenTek,Inc.)
Based on its technologies for diagnosing hormonal health in both men and women and analyzing skin aging, NanoenTek,Inc. is fostering wellness and longevity as its core growth areas. The company’s strategy is to secure growth opportunities in the global market by expanding its business scope beyond medical diagnostics to include personalized health management and beauty tech.
In its wellness business, the company will launch three women’s health diagnostic products—including estradiol, follicle-stimulating hormone (FSH), and free T3—in the U.S. market this month. These products utilize the point-of-care diagnostic platform “FREND” to provide quantitative test results quickly using only a small blood sample.
Estradiol and FSH are key indicators for assessing women’s reproductive health, ovarian function, and menopausal status. Free T3 serves to broaden the diagnostic scope by adding a new test item to the existing thyroid diagnostic products—thyroid-stimulating hormone (TSH) and free thyroxine (Free T4). Through these products, NanoenTek,Inc. plans to address the demand for health management tailored to women’s life stages.
It is also noteworthy that the company is expanding the sales base it has established in the U.S. men’s health clinic market into the women’s health sector. NanoenTek,Inc. anticipates that market opportunities related to hormonal health and wellness will grow in the U.S. due to an aging population and increasing demand for preventive healthcare.
In its longevity business, the company is continuing its collaboration with L’Oréal. The two companies unveiled the “Cell BioPrint,” a skin analysis DEVICE they developed jointly, for the first time at CES 2025. NanoenTek,Inc. aims to strengthen its commercialization foundation in the beauty tech sector by integrating precision diagnostic technology into personalized skincare.
Along with business expansion, the company’s financial performance has continued to grow. NanoenTek,Inc.’s cumulative consolidated revenue for the first three quarters of this year reached 33.5 billion won, a 31.4% increase compared to the same period last year. Sales of its “Friend” in vitro diagnostic device rose 15.6% to 10.1 billion won. Operating profit for the same period stood at 610 million won.
A NanoenTek,Inc. official stated, “The global healthcare industry is shifting beyond the diagnosis and treatment of diseases toward prevention and personalized health management,” adding, “Based on our precision diagnostic technology, we are actively seeking business opportunities in high-growth sectors such as women’s health, wellness, and longevity.”
The official added, “Building on the point-of-care diagnostics business foundation we have established in the U.S. and our collaborations with global partners such as L’Oréal, we will continue to expand our business scope and leverage our technological competitiveness as a driver of medium- to long-term growth.”
Korea Ratings (KRI) took the top spot in the “Credit Rating Reliability” category of the 37th Edaily Survey of Credit Rating Experts (SRE), maintaining its number one position for the fifth consecutiv…
CJ CheilJedang Corp. is taking steps to create a sustainable and safe sports environment by utilizing the biodegradable biomaterial “PHA” (polyhydroxyalkanoates). The company plans to introduce PHA-ba…
Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news. Corestem ChemOn hit the daily upper limit after clarifying its U.S. app…